Raymond James Financial upgraded HLS Therapeutics stock rating to strong-buy on August 14, 2026.
5 reports, 2 independent
Updated Nov 1
No new developments lately
Reached 2 outlets in its first 24 hours
- Reports
- 5
- Developments
- 2
- Repetition
- 60%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Raymond James Financial upgraded HLS Therapeutics stock rating to strong-buy on August 14, 2026.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Raymond James Financial issued a new stock rating upgrade for HLS Therapeutics.1 source
HLS Therapeutics received a strong-buy rating upgrade.1 source
Keep exploring
The entities involved
-
Raymond James Financial
American Investment Bank and Financial Services Firm
Related events
- Raymond James Financial reaffirmed a strong-buy rating and Morgan Stanley set a $25.00 price objective for VIR Biotechnology.
- Raymond James Financial assumed coverage on Xilio Therapeutics shares.
- MarketBeat provided average rating data for Quince Therapeutics, Inc., following a stock rating boost from Raymond James Financial.